Zacks Research Issues Pessimistic Estimate for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Zacks Research reduced their Q2 2026 earnings per share estimates for shares of BioMarin Pharmaceutical in a report released on Wednesday, March 19th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn $0.99 per share for the quarter, down from their previous estimate of $1.00. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s Q3 2026 earnings at $1.05 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $4.09 EPS and FY2027 earnings at $4.79 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million.

A number of other brokerages have also recently weighed in on BMRN. Wedbush reiterated an “outperform” rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Bank of America increased their target price on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. StockNews.com raised shares of BioMarin Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Piper Sandler lifted their price objective on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an “overweight” rating in a research report on Thursday, February 20th. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $94.00.

BioMarin Pharmaceutical Price Performance

BMRN opened at $71.53 on Monday. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. The company’s 50-day moving average price is $66.83 and its 200 day moving average price is $67.78. BioMarin Pharmaceutical has a fifty-two week low of $60.63 and a fifty-two week high of $94.85. The firm has a market cap of $13.65 billion, a price-to-earnings ratio of 32.51, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33.

Insiders Place Their Bets

In related news, CAO Erin Burkhart sold 1,295 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now directly owns 16,955 shares in the company, valued at $1,212,621.60. The trade was a 7.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.85% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

Institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its holdings in shares of BioMarin Pharmaceutical by 2.7% in the fourth quarter. California State Teachers Retirement System now owns 273,761 shares of the biotechnology company’s stock worth $17,994,000 after buying an additional 7,094 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of BioMarin Pharmaceutical by 295.9% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,201 shares of the biotechnology company’s stock valued at $1,525,000 after acquiring an additional 17,340 shares in the last quarter. Lansforsakringar Fondforvaltning AB publ purchased a new position in BioMarin Pharmaceutical during the 4th quarter worth approximately $4,367,000. PKO Investment Management Joint Stock Co purchased a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at $789,000. Finally, Siemens Fonds Invest GmbH acquired a new stake in BioMarin Pharmaceutical during the 4th quarter worth about $821,000. Hedge funds and other institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.